Could Gilead Sciences (GILD) Have a Major HIV Growth Engine in Yeztugo?

3 weeks ago 29

Soumya Eswaran

Tue, August 4, 2026 astatine 10:19 AM CDT 3 min read

Baron Capital, an concern absorption company, released its Q2 2026 capitalist missive for the "Baron Health Care Fund". A transcript of the missive is disposable to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% summation for the Russell 3000 Health Care Index and the 15.44% summation for the Russell 3000 Index. Since inception, the Fund appreciated 10.61% connected an annualized basis, compared with 10.02% for the Benchmark and 14.83% for the Index. Strong banal enactment successful pharmaceuticals, biotechnology, wellness attraction equipment, and beingness sciences tools and services supported the Fund's outperformance, though constricted vulnerability to managed attraction stocks reduced comparative returns. The Fund remains affirmative connected wellness attraction owed to improving biotechnology funding, beardown acquisition activity, recovering managed attraction margins, and maturation from an aging population, chronic disease, aesculapian innovation, and higher wellness attraction spending. In addition, delight cheque the Fund's apical 5 holdings to cognize the champion picks successful 2026.

In its second-quarter 2026 capitalist letter, Baron Health Care Fund highlighted Gilead Sciences, Inc. (NASDAQ:GILD). Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical institution that discovers, develops, and commercializes medicines for unmet aesculapian needs, detracted from the fund's show during the quarter. On August 03, 2026, Gilead Sciences, Inc. (NASDAQ:GILD) closed astatine $131.15 per share. The one-month instrumentality of Gilead Sciences, Inc. (NASDAQ:GILD) was -3.82%, and its shares gained 16.62% implicit the past 52 weeks. Gilead Sciences, Inc. (NASDAQ:GILD) has a marketplace capitalization of $162.83 billion.

Baron Health Care Fund stated the pursuing regarding Gilead Sciences, Inc. (NASDAQ:GILD) in its Q2 2026 capitalist letter:

"Biotechnology institution Gilead Sciences, Inc. (NASDAQ:GILD) is champion known for processing and commercializing therapies that dainty and forestall HIV. Following a beardown first-quarter beforehand driven by continued enthusiasm surrounding the motorboat of Yeztugo for HIV prevention, the banal detracted from show successful the 2nd quarter. Shares pulled backmost aft absorption issued blimpish 2026 guidance successful February, including expectations for astir $800 cardinal of Yeztugo sales, beneath capitalist expectations. Despite the much cautious outlook, we stay assured in Yeztugo's long-term opportunity. Unlike Descovy, a regular oral preventive treatment, Yeztugo is a twice-yearly injectable therapy that has the imaginable to importantly amended diligent compliance. Looking ahead, we proceed to presumption Gilead arsenic a person successful HIV attraction and prevention, with Yeztugo representing an important caller preventive enactment and a promising next-generation pipeline that includes a play oral lenacapavir and islatravir combination being developed with Merck & Co., Inc., arsenic good arsenic a wholly-owned play regimen incorporating a caller integrase inhibitor designed to connection a higher obstruction to resistance."

Read Entire Article